Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Psoriatic Arthritis - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 23 Nov 17

The "Psoriatic Arthritis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2017, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

Psoriatic Arthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 5, 8, 10, 1, 24, 9 and 3 respectively.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Psoriatic Arthritis - Overview
  3. Psoriatic Arthritis - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Psoriatic Arthritis - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Psoriatic Arthritis - Companies Involved in Therapeutics Development
  • 3SBio Inc
  • AbbVie Inc
  • AbGenomics International Inc
  • Aclaris Therapeutics Inc
  • Adello Biologics LLC
  • Allergan Plc
  • Alteogen Inc
  • Amgen Inc
  • Biocon Ltd
  • Bionovis SA
  • Coherus BioSciences Inc
  • Eli Lilly and Co
  • Formycon AG
  • Forward Pharma AS
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • Genor BioPharma Co Ltd
  • Immunwork Inc
  • Innovent Biologics Inc
  • Johnson & Johnson
  • KPI Therapeutics Inc
  • Morphotek Inc
  • Mycenax Biotech Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Novo Nordisk AS
  • Nuevolution AB
  • Oncobiologics Inc
  • Pfizer Inc
  • Reliance Life Sciences Pvt Ltd
  • Rigel Pharmaceuticals Inc
  • Sandoz International GmbH
  • Sun Pharma Advanced Research Company Ltd
  • SynAct Pharma AB
  • UCB SA
  • Xbrane Biopharma AB

For more information about this report visit

View source version on

Business Wire

Last updated on: 23/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.